Biologic therapy Phoenix: what blood-and-tissue joint care means

What to check before standing up

Before standing, notice whether the joint feels stiff, swollen, weak, or hard to bend. Check whether the ache changes after several easy steps.

Morning stiffness may fade as the joint warms. Soreness that builds after chores may point to a different cause.

Write down any sudden change and the day it began. You won't have to recall every detail while the clinician checks your joint.

What to try at home

A quieter day may settle soreness after too much activity. Staying still all day can leave a stiff joint harder to move.

Try an easy walk or gentle strength work if those don't sharply raise the ache. Stop the exercise when the soreness keeps climbing instead of easing.

Heat may loosen stiffness, while cold may calm soreness after activity. Ask your doctor which is safe with your health and medicines.

When to have the soreness checked

Have the joint checked when soreness keeps disturbing sleep, walking, dressing, or stairs. Bring any X-ray, your medicine list, and short notes about earlier care.

The visit begins with when the ache started and which motions hurt. Then the clinician checks movement, strength, swelling, and tender areas.

Ask, “Which part seems sore, and what could be bothering it?” QC Kinetix's medical providers examine the joint and offer regenerative treatments without surgery: they spin blood drawn from an arm or marrow, soft tissue collected inside the pelvis, then put it into the aching joint.

Sources

1. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446; 95% CI $4,550-5,762, n=65) and the mean claimed clinical efficacy was 82% (SD 9.6%; n=36) - a figure the authors describe as a gap between marketing claims and the published literature.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. Journal of Knee Surgery, 2018. DOI: 10.1055/s-0037-1604443.

2. Medicare's national coverage determination states that CMS covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only inside an approved coverage-with-evidence-development clinical study. Every approved study listed under the NCD is a wound-healing study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

3. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

4. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.